Reflections in order to agree on who should be responsible for the deep sedation with propofol in gastrointestinal endoscopies, after so many squabble between anaesthesiologists and endoscopists.

Download full-text PDF

Source
http://dx.doi.org/10.17235/reed.2017.4901/2017DOI Listing

Publication Analysis

Top Keywords

propofol gastrointestinal
8
discussions propofol
4
gastrointestinal endoscopy
4
endoscopy reflections
4
reflections order
4
order agree
4
agree responsible
4
responsible deep
4
deep sedation
4
sedation propofol
4

Similar Publications

Background: Gastrointestinal endoscopy is increasingly performed under sedation in older patients. Aging has implications in increasing the morbidity and the risk of complications related to sedation. The aim of this study is to assess the difference in complications between patients aged 65 to 74 years and those aged over 75 years.

View Article and Find Full Text PDF

Introduction: Endoscopic submucosal dissection (ESD) allows for curative en-bloc resection of dysplastic gastrointestinal (GI) tract lesions. However, it is associated with postoperative adverse events (AEs) such as pain, bleeding, and perforation. Dexmedetomidine, an α2-receptor agonist, has emerged as a promising adjunct sedative for ESD under moderate sedation, offering anxiolysis and analgesia.

View Article and Find Full Text PDF

Introduction: Although propofol is widely preferred as a sedative agent in gastrointestinal endoscopy, its use is commonly associated with hemodynamic adverse events. New sedatives, such as ciprofol, are emerging with promising results. Thus, we aimed to perform a systematic review and meta-analysis to compare efficacy-, safety-, and satisfaction-related outcomes between ciprofol and propofol for adult sedation in gastrointestinal endoscopy.

View Article and Find Full Text PDF

Objectives: Propofol is commonly used for endoscopic sedation. However, it can induce adverse hemodynamic effects. Remimazolam is known to have a fast onset and short duration comparable to that of propofol, but with fewer effects on hemodynamics.

View Article and Find Full Text PDF
Article Synopsis
  • Critically ill patients often experience pain, which can lead to various physiological issues; remifentanil is commonly used for pain relief in ICUs but has significant side effects, prompting the exploration of oliceridine as a potentially safer alternative.
  • A multicenter trial in China will compare oliceridine and remifentanil in 292 mechanically ventilated patients, focusing on pain and sedation management using specific observational scales.
  • The primary outcome is the percentage of time patients remain within target pain relief during treatment, while secondary outcomes will assess factors like side effects, sedation needs, and overall ICU recovery metrics.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!